PL2861229T3 - Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitową - Google Patents
Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitowąInfo
- Publication number
- PL2861229T3 PL2861229T3 PL13728758T PL13728758T PL2861229T3 PL 2861229 T3 PL2861229 T3 PL 2861229T3 PL 13728758 T PL13728758 T PL 13728758T PL 13728758 T PL13728758 T PL 13728758T PL 2861229 T3 PL2861229 T3 PL 2861229T3
- Authority
- PL
- Poland
- Prior art keywords
- microbiote
- tryptophane
- nicotinamide
- intestinal
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012011890 | 2012-06-15 | ||
| PCT/EP2013/062363 WO2013186355A1 (en) | 2012-06-15 | 2013-06-14 | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
| EP13728758.7A EP2861229B1 (en) | 2012-06-15 | 2013-06-14 | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2861229T3 true PL2861229T3 (pl) | 2021-08-09 |
Family
ID=47002494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13728758T PL2861229T3 (pl) | 2012-06-15 | 2013-06-14 | Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitową |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US10426765B2 (pl) |
| EP (2) | EP2861229B1 (pl) |
| JP (3) | JP6855165B2 (pl) |
| KR (2) | KR102211832B1 (pl) |
| CN (2) | CN108273064A (pl) |
| AR (1) | AR091465A1 (pl) |
| AU (1) | AU2013276451B2 (pl) |
| BR (1) | BR112014030835B1 (pl) |
| CA (1) | CA2876540C (pl) |
| CY (1) | CY1123999T1 (pl) |
| DK (1) | DK2861229T3 (pl) |
| ES (1) | ES2859758T3 (pl) |
| HR (1) | HRP20210090T1 (pl) |
| HU (1) | HUE053359T2 (pl) |
| IL (1) | IL236205B (pl) |
| IN (1) | IN2014DN10260A (pl) |
| JO (1) | JO3578B1 (pl) |
| LT (1) | LT2861229T (pl) |
| MX (1) | MX370795B (pl) |
| NZ (1) | NZ702297A (pl) |
| PH (1) | PH12014502744A1 (pl) |
| PL (1) | PL2861229T3 (pl) |
| PT (1) | PT2861229T (pl) |
| RS (1) | RS61288B1 (pl) |
| RU (1) | RU2657797C2 (pl) |
| SA (1) | SA113340643B1 (pl) |
| SG (1) | SG11201408251SA (pl) |
| SI (1) | SI2861229T1 (pl) |
| SM (1) | SMT202100248T1 (pl) |
| TW (1) | TWI624260B (pl) |
| WO (1) | WO2013186355A1 (pl) |
| ZA (1) | ZA201408922B (pl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2876540C (en) | 2012-06-15 | 2022-11-29 | Conaris Research Institute Ag | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
| PL3003298T3 (pl) * | 2013-06-05 | 2024-07-15 | The University Of British Columbia | Związki antyfibrogenne, sposoby ich zastosowania |
| US10456389B2 (en) * | 2013-06-14 | 2019-10-29 | Conaris Research Institute Ag | Extended release nicotinamide formulation |
| JP6895752B2 (ja) | 2013-12-13 | 2021-06-30 | コナリス リサーチ インスティチュート アーゲー | ニコチン酸および／またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物 |
| EP2884282A1 (en) | 2013-12-13 | 2015-06-17 | CONARIS research institute AG | Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency |
| ES2716115T3 (es) | 2013-12-13 | 2019-06-10 | Conaris Res Institute Ag | Una composición farmacéutica que contiene conbinaciones de nicotinamida y ácido 5-aminosalicílico para influir de forma beneficiosa en la microbiota intestinal y/o tratar la inflamación gastrointestinal |
| WO2015124637A1 (en) * | 2014-02-18 | 2015-08-27 | Conaris Research Institute Ag | Methods and compositions for intestinal microenvironment transfer |
| CN106413680A (zh) * | 2014-05-12 | 2017-02-15 | 荷兰联合利华有限公司 | 用于诱导抗微生物肽生成的烟酰胺 |
| CN105287561A (zh) * | 2015-11-25 | 2016-02-03 | 上海交通大学医学院附属瑞金医院 | 一种治疗溃疡性结肠炎的药物组合物 |
| CA3021022C (en) * | 2016-04-14 | 2024-04-23 | ChromaDex Inc. | Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula |
| ES2848575T3 (es) * | 2016-04-19 | 2021-08-10 | Conaris Res Institute Ag | Composiciones farmacéuticas orales de nicotinamida |
| CN109310642B (zh) | 2016-04-19 | 2021-07-20 | 费灵有限公司 | 美沙拉嗪的口服药物组合物 |
| CN109718234A (zh) * | 2017-10-31 | 2019-05-07 | 中国农业大学 | L-色氨酸在缓解肠道炎症反应和屏障功能紊乱中的应用 |
| CN108935981B (zh) * | 2018-06-05 | 2026-05-05 | 西北农林科技大学 | 围产期奶山羊添加烟酰胺对羔羊糖脂代谢的影响及其机制 |
| EP3925450A4 (en) * | 2019-02-12 | 2022-09-21 | Megumi Tanaka | FOOD OR DRINK FOR BABIES AND INFANTS, METHODS OF IMPROVING THE INTESTINAL ENVIRONMENT OF A BABY OR INFANTS, AND METHODS OF BOOSTING THE IMMUNITY OF A BABY OR INFANTS |
| US12357612B2 (en) | 2019-03-28 | 2025-07-15 | Tohoku University | Prophylactic or therapeutic agent for cancer |
| CN113398130A (zh) * | 2020-03-16 | 2021-09-17 | 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） | 烟酰胺用于预防和治疗胃肠道功能紊乱的用途 |
| JP2023550994A (ja) * | 2020-11-27 | 2023-12-06 | コナリス リサーチ インスティテュート アクチェンゲゼルシャフト | Ｃｏｖｉｄ－１９及びその他のウイルス感染症の患者の症状の消散までの時間を低減するためのニコチンアミド、ニコチンアミド前駆体及びニコチンアミド代謝体並びにそれらの組成物 |
| CN116635025A (zh) * | 2020-11-27 | 2023-08-22 | 康纳里斯研究院股份公司 | 用于缩短covid-19和其他病毒感染患者的症状消退时间的烟酰胺、烟酰胺前体和烟酰胺代谢物及其组合物 |
| JPWO2023002939A1 (pl) * | 2021-07-19 | 2023-01-26 | ||
| EP4499059A1 (en) * | 2022-03-30 | 2025-02-05 | CONARIS research institute AG | Composition comprising nicotinamide, nicotinamide precursors, nicotinamide metabolites or combinations thereof for preventing or reducing one or more post-acute symptoms of infectious diseases |
| KR102789810B1 (ko) | 2023-02-06 | 2025-03-31 | 한림대학교 산학협력단 | 아토피 피부염 진단용 바이오마커 |
| CN117837697A (zh) * | 2023-12-22 | 2024-04-09 | 汕头大学 | 一种烟酰胺的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6129930A (en) | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| DE19524928A1 (de) * | 1995-07-08 | 1997-01-09 | Basf Ag | Verfahren zur Rektifikation von Gemischen hochsiedender luft- und/oder temperaturempfindlicher Substanzen, die eine hohe Trennleistung erfordern, im Feinvakuum, sowie für dieses Verfahren geeignete Kolonnen |
| US5846983A (en) * | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| US5736532A (en) * | 1996-02-14 | 1998-04-07 | Furda; Ivan | Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan |
| GB9614902D0 (en) * | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
| KR20010102963A (ko) * | 1998-12-23 | 2001-11-17 | 윌리암스 로저 에이 | 심장 혈관 징후를 위한 회장 담즙산 수송 저해제와니코틴산 유도체의 조합물 |
| US6713057B1 (en) | 1999-02-24 | 2004-03-30 | The Johns Hopkins University | Compositions and methods for modulating serum cholesterol |
| GB0015242D0 (en) | 2000-06-22 | 2000-08-16 | Nycomed Amersham Plc | Stabiliser for radiopharmaceuticals |
| WO2002011725A1 (en) | 2000-08-08 | 2002-02-14 | Shionogi & Co., Ltd. | Inflammatory cytokine production inhibitors |
| US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
| US7417037B2 (en) | 2004-01-20 | 2008-08-26 | The Board Of Regents Of The University Of Oklahoma | Compositions and methods of treatment for inflammatory diseases |
| US20060264409A1 (en) | 2004-01-20 | 2006-11-23 | Harty Richard F | Compositions and methods of treatment for inflammatory diseases |
| WO2005115075A2 (en) | 2004-05-27 | 2005-12-08 | Antibe Therapeutics Inc. | Salt of 4- or 5- aminosalicylic acid |
| CA2581816A1 (en) * | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Microcapsules comprising a methylxanthine and a corticosteroid |
| JPWO2007004613A1 (ja) * | 2005-07-01 | 2009-01-29 | 味の素株式会社 | 炎症性腸疾患治療薬及びＴＮＦ−α産生抑制剤 |
| DK2026651T3 (da) * | 2006-03-08 | 2013-07-08 | Cortria Corp | Kombinationsterapi med ikke-selektive COX-inhibitorer til forebyggelse af COX-relaterede maveskader |
| ITMI20061932A1 (it) | 2006-10-09 | 2008-04-10 | Carlo Ghisalberti | Complessi a trasferimento di carica per uso medicale |
| EP1935422A1 (en) * | 2006-12-20 | 2008-06-25 | PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG | Pharmaceutical composition comprising nicotinamide or nicotinic acid |
| US20090104171A1 (en) * | 2007-10-19 | 2009-04-23 | Pardee Joel D | Metabolic Enhancement Therapy |
| EP2276491A4 (en) * | 2008-04-25 | 2011-08-17 | Karolinska Inst Innovations Ab | NEW THERAPY FOR THE TREATMENT OF IRRITATION SYNDROME |
| AU2009249600A1 (en) * | 2008-05-20 | 2009-11-26 | Cerenis Therapeutics Holding S.A. | Niacin and NSAID for combination therapy |
| MX2010013169A (es) | 2008-06-02 | 2010-12-21 | Reddy S Lab Ltd | Formulaciones de niacina de liberacion modificada. |
| WO2010040113A1 (en) | 2008-10-03 | 2010-04-08 | Salix Pharmaceuticals, Ltd. | Compositions and methods for the treatment of bowel diseases with granulated mesalamine |
| JP2011121889A (ja) | 2009-12-09 | 2011-06-23 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用アミノ酸組成物 |
| JP2012102054A (ja) | 2010-11-11 | 2012-05-31 | Kyodo Milk Industry Co Ltd | 腸内ポリアミン増強剤 |
| WO2012090224A1 (en) | 2010-12-29 | 2012-07-05 | Nutracryst Therapeutics Private Limited | Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug |
| CA2876540C (en) | 2012-06-15 | 2022-11-29 | Conaris Research Institute Ag | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
| US10456389B2 (en) | 2013-06-14 | 2019-10-29 | Conaris Research Institute Ag | Extended release nicotinamide formulation |
| ES2848575T3 (es) | 2016-04-19 | 2021-08-10 | Conaris Res Institute Ag | Composiciones farmacéuticas orales de nicotinamida |
| JP2023550994A (ja) * | 2020-11-27 | 2023-12-06 | コナリス リサーチ インスティテュート アクチェンゲゼルシャフト | Ｃｏｖｉｄ－１９及びその他のウイルス感染症の患者の症状の消散までの時間を低減するためのニコチンアミド、ニコチンアミド前駆体及びニコチンアミド代謝体並びにそれらの組成物 |
-
2013
- 2013-06-14 CA CA2876540A patent/CA2876540C/en active Active
- 2013-06-14 KR KR1020207002601A patent/KR102211832B1/ko active Active
- 2013-06-14 AU AU2013276451A patent/AU2013276451B2/en active Active
- 2013-06-14 RU RU2014148239A patent/RU2657797C2/ru active
- 2013-06-14 HU HUE13728758A patent/HUE053359T2/hu unknown
- 2013-06-14 HR HRP20210090TT patent/HRP20210090T1/hr unknown
- 2013-06-14 RS RS20201595A patent/RS61288B1/sr unknown
- 2013-06-14 EP EP13728758.7A patent/EP2861229B1/en active Active
- 2013-06-14 IN IN10260DEN2014 patent/IN2014DN10260A/en unknown
- 2013-06-14 CN CN201810359182.XA patent/CN108273064A/zh active Pending
- 2013-06-14 SI SI201331842T patent/SI2861229T1/sl unknown
- 2013-06-14 WO PCT/EP2013/062363 patent/WO2013186355A1/en not_active Ceased
- 2013-06-14 SM SM20210248T patent/SMT202100248T1/it unknown
- 2013-06-14 ES ES13728758T patent/ES2859758T3/es active Active
- 2013-06-14 US US14/407,780 patent/US10426765B2/en active Active
- 2013-06-14 NZ NZ702297A patent/NZ702297A/en unknown
- 2013-06-14 PT PT137287587T patent/PT2861229T/pt unknown
- 2013-06-14 CN CN201380031622.4A patent/CN104363907A/zh active Pending
- 2013-06-14 MX MX2014015217A patent/MX370795B/es active IP Right Grant
- 2013-06-14 KR KR20147036089A patent/KR20150021071A/ko not_active Ceased
- 2013-06-14 JP JP2015516627A patent/JP6855165B2/ja active Active
- 2013-06-14 PL PL13728758T patent/PL2861229T3/pl unknown
- 2013-06-14 EP EP20214819.3A patent/EP3831379B1/en active Active
- 2013-06-14 SG SG11201408251SA patent/SG11201408251SA/en unknown
- 2013-06-14 DK DK13728758.7T patent/DK2861229T3/da active
- 2013-06-14 LT LTEP13728758.7T patent/LT2861229T/lt unknown
- 2013-06-14 BR BR112014030835-7A patent/BR112014030835B1/pt active IP Right Grant
- 2013-06-15 SA SA113340643A patent/SA113340643B1/ar unknown
- 2013-06-16 JO JOP/2013/0182A patent/JO3578B1/ar active
- 2013-06-17 TW TW102121395A patent/TWI624260B/zh active
- 2013-06-17 AR ARP130102127 patent/AR091465A1/es unknown
-
2014
- 2014-12-04 ZA ZA2014/08922A patent/ZA201408922B/en unknown
- 2014-12-05 PH PH12014502744A patent/PH12014502744A1/en unknown
- 2014-12-11 IL IL236205A patent/IL236205B/en active IP Right Grant
-
2018
- 2018-12-13 JP JP2018233038A patent/JP2019069972A/ja active Pending
-
2019
- 2019-09-16 US US16/572,494 patent/US20200009124A1/en active Pending
-
2021
- 2021-03-02 CY CY20211100172T patent/CY1123999T1/el unknown
- 2021-10-15 JP JP2021169322A patent/JP2022017332A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2861229T (pt) | Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida e/ou triptofano para influenciar positivamente a microbiota intestinal | |
| IL236036A0 (en) | Pyridinone and pyridizinone derivatives | |
| DK2742019T3 (da) | N1-cyklisk amin-n5-substituerede phenylbiguanidderivater og farmaceutisk sammensætning, der omfatter disse | |
| CO6970616A2 (es) | Composición herbicida que contiene ácido de 4-amino-3-cloro-6-(4-cloro-2-flúor -3-metoxifenil) piridina-2-carboxílico, o los derivados del mismo y fluroxipir, o los derivados del mismo | |
| CO7071126A2 (es) | Derivados de piridona | |
| CO6910189A2 (es) | Derivado heterociclico y farmacéutico | |
| IL236852B (en) | Herbicidal compositions comprising 4-amino-3-chloro-5-fluoro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acid or a derivative thereof and certain ps ii inhibitors | |
| HUE054178T2 (hu) | Metil/fluor-piridinil-metoxi-szubsztituált piridinon-piridinil-vegyületek és fluor-pirimidinil-metoxi-szubsztituált piridinon-piridinil-vegyületek | |
| LT2892912T (lt) | Oleanolio rūgšties c17-alkandiilo ir alkendiilo dariniai bei jų panaudojimo būdai | |
| IL236863B (en) | Herbicidal compositions comprising 4-amino-3-chloro-5-fluoro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acid or a derivative thereof and imidazolinones | |
| HUE037736T2 (hu) | Piridin származékok | |
| IL236499A0 (en) | Compounds that suppress nicotinamide phosphoribosyltransferase (nampt), preparations containing them and their uses | |
| BR112014027561A2 (pt) | moduladores alostéricos dos receptor acetilcolina alfa 7 nicotínicos, seus derivados e respectivas utilizações | |
| PT2706062T (pt) | Novos derivados da cefalosporina e sua composição farmacêutica | |
| DK2917181T3 (da) | Heteroarylderivater og anvendelser deraf | |
| PT3079675T (pt) | Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida para utilização para influenciar beneficamente os níveis de lípidos no sangue através da modificação da microbiota intestinal | |
| IL238370A0 (en) | n-(pyridin-2-yl)pyrimidine-4-amine derivatives containing a sulfoximine group | |
| IL256646B (en) | History of azaquinazoline carboxamides and pharmaceutical preparations containing them | |
| EP2810941A4 (en) | NOVEL PIPERIN DERIVATIVE AND USE THEREOF | |
| ZA201305227B (en) | Pharmaceutical composition comprising pyridone derivatives | |
| EP2789607A4 (en) | PYRIDONE DERIVATIVE AND MEDICAMENT THEREFOR | |
| SG11201406942SA (en) | Trans-2-decenoic acid derivative and drug containing same | |
| CL2015001778A1 (es) | Composiciones herbicidas que contienen ácido de 4-amino-3-cloro-6-(4-cloro-2-flúor-3-metoxifenil) piridina-2-carboxílico o un derivado del mismo y flufenacet | |
| IL240447A (en) | Propionic Acid-Baryl Acid Derivatives and Their Use as Pharmaceutical Preparations | |
| TH1401007439A (th) | องค์ประกอบทางเภสัชกรรมที่มีนิโคตินิกแอซิด และ/หรือ นิโคตินาไมด์ และ/หรือ ทริปโตฟานเพื่อการมีอิทธิพลในด้านบวกต่อจุลชีพประจำถิ่นในลำไส้ |